POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
| Autor: | Holleman, MS, Santi, I, Huygens, S, Aben, KKH, Van den Bergh, ACM, Bergman, AM, van den Eertwegh, AJM, Kuppen, MCP, Lavalaye, J, Mehra, NM, van Moorselaar, RJA, Van Oort, IM, Somford, DM, Westgeest, HM, Gerritsen, WR, Uyl-De Groot, CA |
|---|---|
| Zdroj: | In Value in Health January 2022 25(1) Supplement:S266-S267 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect